Sixth Street-backed Caris Life Sciences targets $5.3 billion valuation in US IPO
Irving, Texas-based Caris plans to raise up to $424 million by offering 23.5 million shares priced between $16 and $18 apiece.
The IPO market is heating up as high-profile companies move ahead with their stock market listings in a calmer period after tariff-related volatility stifled deal activity earlier this year.
In 2021, Caris raised $830 million at a $7.83 billion valuation in a funding round led by investment firm Sixth Street.
Caris will trade on the Nasdaq under the symbol "CAI."
BofA Securities, J.P. Morgan, Goldman Sachs, and Citigroup are the lead underwriters for the offering.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
a few seconds ago
- Associated Press
3 principles to invest by, whatever comes next
I recently opened a second-quarter investment account statement, not to euphoria—but relief. Let's not forget, US equities flirted with a bear market earlier this year. There were concerns that China's DeepSeek artificial intelligence would bring down US technology titans. There were the tariffs. Yet, here we sit in the third quarter of 2025 with the Morningstar US Market Index up nearly 8% for the year and the Morningstar US Core Bond Index having returned more than 3%. Ahead of us lie multiple pathways. Economic data and earnings announcements will provide direction, but there are also 'unknown unknowns' that could alter our course. Here are three investment principles to keep in mind. Principle 1: Where the market goes, nobody knows Coming into the year, how many pundits talked about AI out of China challenging US tech stocks? Did anyone expect tariffs to be such a factor? Though 2025 has had its plot twists, changes in market direction are hardly unusual. Consider thatstocks came into summer 2024 on a tear, beforesentiment turned. A series of releases—jobs, inflation, and earnings—compounded fears of a narrow and pricey market. Somehow, both an unexpected interest rate hike by the Bank of Japan and an expected rate cut by the Fed triggered selloffs. But markets recovered. Election results in November sparked a powerful rally. So, w here we go from here is anyone's guess. But I'll cite a story about how dead investors outperform living ones because they don't trade. Buy-and-hold has been a great strategy for long-term investors. Principle 2: Global investing can pay off Some think you don't need to own anything other than US equities. But I'llnote that the Morningstar Global Markets ex-US Index has trounced its US equivalent so far in 2025. What's behind the turnaround? The dollar weakening against many other currencies is part of the story. But markets in many regions—Europe, Latin America, and India—have roared to life this year. To me, global investing is about casting the net as widely as possible. So, just as some argue that US-based multinationals provide American investors with global exposure, you could also argue that they're not fully exposed to the US, from a revenue perspective, with a purely domestic portfolio. Principle 3: Bonds aren't broken The equity market's extreme volatility in 2025 makes bonds look like steady-Eddies. While US stocks were in free fall from late February through early April, the Morningstar US Core Bond Index gained 1.3%. Bonds diversified equities, serving as portfolio ballast. Bonds face a lot of 'headline risk.' There are debt and deficit concerns. And the shadow of 2022's ' worst bond market ever ' lingers. While the risks are undeniable, fixed income is also the victim of fearmongering. Not only have bonds diversified stocks, they're also providing above-inflation income streams. Thanks to the painful interest rate hikes of 2022-23, yields on fixed income are at levels not seen since the mid-2000s. The road ahead We're likely to see more twists before 2025 is out. Short-term asset-price fluctuations are driven by a complex interplay of variables—macro and micro, fundamental and technical. Longer term, valuation can be a useful guide. According to my Morningstar Equity Research colleagues, the US stock market looked a bit pricey coming into the second half of 2025—not in dangerous bubble territory, but 'trading at a slight premium.' The bargains cluster on the value side of the market and in smaller-cap stocks. Meanwhile, my colleagues in Morningstar Investment Management continue to see upside in bonds and international equities. As always, a buy-and-hold mindset and a diversified portfolio remain sensible investment tactics. ____ This article was provided to The Associated Press by Morningstar. For more markets content, go to Dan Lefkovitz is a strategist for Morningstar Indexes.
Associated Press
a few seconds ago
- Associated Press
REPL Investor Alert: Kessler Topaz Meltzer & Check, LLP Urges REPL Investors with Losses to Contact the Firm
RADNOR, PA - August 21, 2025 ( NEWMEDIAWIRE ) - The law firm of Kessler Topaz Meltzer & Check, LLP ( ) informs investors that a securities class action lawsuit has been filed against Replimune Group, Inc. ('Replimune') ( NASDAQ: REPL ) on behalf of those who purchased or otherwise acquired Replimune securities between November 22, 2024, and July 21, 2025, inclusive (the 'Class Period'). The lead plaintiff deadline is September 22, 2025. CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered Replimune losses, you may CLICK HERE or copy and paste the following link into your browser: You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected]. DEFENDANTS' ALLEGED MISCONDUCT: The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material facts about the company's business, operations, and prospects. Specifically, Defendants misrepresented and/or failed to disclose that: (1) Replimune overstated the trial's prospects for the company's lead product candidate; and (2) as a result, Defendants' statements about the company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. THE LEAD PLAINTIFF PROCESS: Replimune investors may, no later than September 22, 2025, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. Kessler Topaz Meltzer & Check, LLP encourages Replimune investors who have suffered significant losses to contact the firm directly to acquire more information. CLICK HERE TO SIGN UP FOR THE CASE OR GO TO: ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP: Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit CONTACT: Kessler Topaz Meltzer & Check, LLP Jonathan Naji, Esq. (484) 270-1453 280 King of Prussia Road Radnor, PA 19087 [email protected] May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes. View the original release on
Associated Press
a few seconds ago
- Associated Press
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortinet, Inc.
NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Fortinet, Inc. ('Fortinet' or the 'Company') (NASDAQ: FTNT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Fortinet and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On August 6, 2025, Fortinet reported disappointing second quarter 2025 financial results. In response, Investor's Business Daily quoted William Blair analyst Jonathan Ho as stating, 'Investors were left confused by the company's formal statement that 40% to 50% of its accelerated firewall refresh (estimated to be a $450 million, 650,000 unit opportunity) was now completed. This is driving confusion about why Fortinet is not seeing stronger product revenue growth and billings materialize.' On this news, Fortinet's stock price fell $21.28 per share, or 22.03%, to close at $75.30 per share on August 7, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP [email protected] 646-581-9980 ext. 7980
